These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a single technology appraisal. Mowatt G; Boachie C; Crowther M; Fraser C; Hernández R; Jia X; Ternent L Health Technol Assess; 2009 Sep; 13 Suppl 2():63-8. PubMed ID: 19804691 [TBL] [Abstract][Full Text] [Related]
4. Romiplostim: a review of its use in immune thrombocytopenia. Keating GM Drugs; 2012 Feb; 72(3):415-35. PubMed ID: 22316355 [TBL] [Abstract][Full Text] [Related]
5. Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura. Jamali F; Lemery S; Ayalew K; Robottom S; Robie-Suh K; Rieves D; Pazdur R Oncology (Williston Park); 2009 Jul; 23(8):704-9. PubMed ID: 19711585 [TBL] [Abstract][Full Text] [Related]
6. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. Tarantino MD; Bussel JB; Blanchette VS; Despotovic J; Bennett C; Raj A; Williams B; Beam D; Morales J; Rose MJ; Carpenter N; Nie K; Eisen M Lancet; 2016 Jul; 388(10039):45-54. PubMed ID: 27103127 [TBL] [Abstract][Full Text] [Related]
7. Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP). Boyers D; Jia X; Crowther M; Jenkinson D; Fraser C; Mowatt G Health Technol Assess; 2011 May; 15 Suppl 1():23-32. PubMed ID: 21609650 [TBL] [Abstract][Full Text] [Related]
8. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag. Chouhan JD; Herrington JD Pharmacotherapy; 2010 Jul; 30(7):666-83. PubMed ID: 20575632 [TBL] [Abstract][Full Text] [Related]
9. The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital. Marquínez-Alonso I; Escudero-Vilaplana V; Pernía S; Beléndez Bieler C; Fernández-Llamazares CM; Sanjurjo-Sáez M J Clin Pharm Ther; 2014 Aug; 39(4):376-82. PubMed ID: 24702274 [TBL] [Abstract][Full Text] [Related]
10. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP). Bussel JB; Hsieh L; Buchanan GR; Stine K; Kalpatthi R; Gnarra DJ; Ho RH; Nie K; Eisen M Pediatr Blood Cancer; 2015 Feb; 62(2):208-213. PubMed ID: 25345874 [TBL] [Abstract][Full Text] [Related]
11. Romiplostim: a breakthrough treatment for the management of immune thrombocytopenic purpura. Newland A Eur J Haematol Suppl; 2009 Mar; (71):20-5. PubMed ID: 19200304 [TBL] [Abstract][Full Text] [Related]
12. Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial. Shirasugi Y; Ando K; Miyazaki K; Tomiyama Y; Okamoto S; Kurokawa M; Kirito K; Yonemura Y; Mori S; Usuki K; Iwato K; Hashino S; Wei H; Lizambri R Int J Hematol; 2011 Jul; 94(1):71-80. PubMed ID: 21706145 [TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Bussel JB; Buchanan GR; Nugent DJ; Gnarra DJ; Bomgaars LR; Blanchette VS; Wang YM; Nie K; Jun S Blood; 2011 Jul; 118(1):28-36. PubMed ID: 21502541 [TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Bussel JB; Kuter DJ; Pullarkat V; Lyons RM; Guo M; Nichol JL Blood; 2009 Mar; 113(10):2161-71. PubMed ID: 18981291 [TBL] [Abstract][Full Text] [Related]
15. A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura. Shirasugi Y; Ando K; Hashino S; Nagasawa T; Kurata Y; Kishimoto Y; Iwato K; Ohtsu T; Berger DP Int J Hematol; 2009 Sep; 90(2):157-165. PubMed ID: 19543952 [TBL] [Abstract][Full Text] [Related]
16. An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP). Shirasugi Y; Ando K; Miyazaki K; Tomiyama Y; Iwato K; Okamoto S; Kurokawa M; Kirito K; Hashino S; Ninomiya H; Mori S; Yonemura Y; Usuki K; Wei H; Lizambri R Int J Hematol; 2012 Jun; 95(6):652-9. PubMed ID: 22532046 [TBL] [Abstract][Full Text] [Related]
17. Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia. Tarantino MD; Bussel JB; Blanchette VS; Beam D; Roy J; Despotovic J; Raj A; Carpenter N; Mehta B; Eisen M Haematologica; 2019 Nov; 104(11):2283-2291. PubMed ID: 30846500 [TBL] [Abstract][Full Text] [Related]
18. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. Bussel JB; Kuter DJ; George JN; McMillan R; Aledort LM; Conklin GT; Lichtin AE; Lyons RM; Nieva J; Wasser JS; Wiznitzer I; Kelly R; Chen CF; Nichol JL N Engl J Med; 2006 Oct; 355(16):1672-81. PubMed ID: 17050891 [TBL] [Abstract][Full Text] [Related]